Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Andrews

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Neurocritical Care|August 23, 2021
CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) TrialMichael L James, Jesse Troy, Nathaniel Nowacki, et al.
Neurocritical Care|June 24, 2022
Correction to: CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) TrialMichael L James, Jesse Troy, Nathaniel Nowacki, et al.
The Lancet. Infectious Diseases|September 18, 2022
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trialHeather Platt, Tosin Omole, Jose Cardona, et al.
Vaccine|September 7, 2021
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)Joon-Young Song, Chih-Jen Chang, Charles Andrews, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 30, 2018
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and OlderDesmond Curran, Lidia Oostvogels, Thomas Heineman, et al.
American Journal of Respiratory and Critical Care Medicine|February 10, 2007
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary diseaseStephen I Rennard, Charles Fogarty, Steven Kelsen, et al.
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
The Journal of Infectious Diseases|March 13, 2018
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or OlderAnthony L Cunningham, Thomas C Heineman, Himal Lal, et al.
Open Forum Infectious Diseases|June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 YearsRafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
Frontline Gastroenterology|May 19, 2020
Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UKRukshana Kapasi, Jackie Glatter, Christopher A Lamb, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Neurocritical Care|August 23, 2021
CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) TrialMichael L James, Jesse Troy, Nathaniel Nowacki, et al.
Neurocritical Care|June 24, 2022
Correction to: CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) TrialMichael L James, Jesse Troy, Nathaniel Nowacki, et al.
The Lancet. Infectious Diseases|September 18, 2022
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trialHeather Platt, Tosin Omole, Jose Cardona, et al.
Vaccine|September 7, 2021
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)Joon-Young Song, Chih-Jen Chang, Charles Andrews, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 30, 2018
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and OlderDesmond Curran, Lidia Oostvogels, Thomas Heineman, et al.
American Journal of Respiratory and Critical Care Medicine|February 10, 2007
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary diseaseStephen I Rennard, Charles Fogarty, Steven Kelsen, et al.
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
The Journal of Infectious Diseases|March 13, 2018
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or OlderAnthony L Cunningham, Thomas C Heineman, Himal Lal, et al.
Open Forum Infectious Diseases|June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 YearsRafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
Frontline Gastroenterology|May 19, 2020
Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UKRukshana Kapasi, Jackie Glatter, Christopher A Lamb, et al.
Pageof 4